TY - JOUR
T1 - Intranasal delivery of nanotherapeutics/ nanobiotherapeutics for the treatment of Alzheimer’s disease
T2 - A proficient approach
AU - Dhas, Namdev L.
AU - Kudarha, Ritu R.
AU - Mehta, Tejal A.
N1 - Funding Information:
The authors thank Nirma University, Ahmedabad, Gujarat, India, Council for Scientific and Industrial Research, and DST-INSPIRE, New Delhi, India, for providing financial assis-
Funding Information:
The authors thank Nirma University, Ahmedabad, Gujarat, India, Council for Scientific and Industrial Research, and DST-INSPIRE, New Delhi, India, for providing financial assistance in the form of a Nirma University Fellowship, CSIR-SRF, and INSPIRE fellowship, respectively, to Namdev Dhas (NU/IP/stipend/Ph.D./2016/), (09/1048(007)/2018-EMR-I, and Ritu Kudarha (No. DST/INSPIRE Fellowship/2015/IF150242).
Publisher Copyright:
© 2019 Begell House, Inc.
PY - 2019
Y1 - 2019
N2 - Therapeutics and biotherapeutics-based fabrication of nanoparticles has fascinated scientists since the past two decades and exciting challenges have been surmounted. Particular interest has been paid to the exploitation of functionalized nanocarriers in the treatment of Alzheimer’s disease (AD) using nasal route. Development of various material-based nanocarriers is a common approach to obtain advanced drug delivery systems possessing the ability to follow intranasal (IN) route for brain targeting, which would ultimately ameliorate the effect of AD. This review highlights the various pathological theories for AD along with their controversies. This work intends to provide a thorough, up-to-date, and holistic discussion on various pathways for nose-to-brain delivery and different formulation factors impacting on nasal absorption. The various material properties and their engineered nanocarriers as a smart delivery system, including synergistic effect of therapeutic/biotherapeutic agent in IN delivery as well as in AD therapy have been discussed. This review also emphasizes toxicity, especially neurotoxicity concerns pertaining to drug delivery systems.
AB - Therapeutics and biotherapeutics-based fabrication of nanoparticles has fascinated scientists since the past two decades and exciting challenges have been surmounted. Particular interest has been paid to the exploitation of functionalized nanocarriers in the treatment of Alzheimer’s disease (AD) using nasal route. Development of various material-based nanocarriers is a common approach to obtain advanced drug delivery systems possessing the ability to follow intranasal (IN) route for brain targeting, which would ultimately ameliorate the effect of AD. This review highlights the various pathological theories for AD along with their controversies. This work intends to provide a thorough, up-to-date, and holistic discussion on various pathways for nose-to-brain delivery and different formulation factors impacting on nasal absorption. The various material properties and their engineered nanocarriers as a smart delivery system, including synergistic effect of therapeutic/biotherapeutic agent in IN delivery as well as in AD therapy have been discussed. This review also emphasizes toxicity, especially neurotoxicity concerns pertaining to drug delivery systems.
UR - http://www.scopus.com/inward/record.url?scp=85075256361&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075256361&partnerID=8YFLogxK
U2 - 10.1615/CritRevTherDrugCarrierSyst.2018026762
DO - 10.1615/CritRevTherDrugCarrierSyst.2018026762
M3 - Article
C2 - 32421951
AN - SCOPUS:85075256361
SN - 0743-4863
VL - 36
SP - 373
EP - 447
JO - Critical Reviews in Therapeutic Drug Carrier Systems
JF - Critical Reviews in Therapeutic Drug Carrier Systems
IS - 5
ER -